Corporate Strategy & Transformation

SHERIDAN, WYOMING - December 8, 2025 - Kellanova is using its "Cool Soil Critters" campaign in Australia to turn an often invisible topic-soil health-into a mainstream sustainability and supply-chain conversation, linking biodiversity beneath the surface directly to crop resilience, food security and long-term brand value.

From Iconic Foods to the Health of the Soil Behind Them

As a company that depends on crops to make the foods people know and love, Kellanova is positioning soil health as a strategic asset rather than a purely agronomic concern. Through its partnership with the Cool Soil Initiative, Kellanova Australia and New Zealand (ANZ) is supporting programs that help farmers increase organic carbon levels and reduce greenhouse gas emissions on Australian farms.

SHERIDAN, WYOMING - December 4, 2025 - Thumzup Media Corporation is moving quickly to shed its image as a niche social advertising startup and reposition itself as a diversified operator in digital-asset infrastructure, data-center capacity, and next-generation computation. Backed by fresh capital and a pipeline of deals, the Los Angeles-based company is steering toward businesses with more predictable cash flows and scalable hard assets.

From Social Ad Startup to Balance-Sheet Builder

Thumzup's strategic reset rests on a markedly stronger financial base. In August 2025, the company raised $50 million in a public offering, lifting total assets to approximately $52 million. That step-change in scale gives Thumzup, which previously operated with far leaner resources, a genuine platform to pursue acquisitions, infrastructure buildouts, and selective minority stakes across high-growth technology verticals.

SHERIDAN, WYOMING - December 2, 2025 - After years of volatility in Alzheimer's R&D, Roche's re-emergence with positive early data for trontinemab is reshaping expectations for the next competitive cycle in disease-modifying therapies, signaling that big pharma is not done pushing for better outcomes in this high-risk, high-need market.

From Aduhelm's fallout to a more mature Alzheimer's market

The modern Alzheimer's era was defined-some would say scarred-by the 2021 approval of Biogen and Eisai's Aduhelm, a controversial and costly monoclonal antibody that ultimately failed to deliver convincing clinical benefit and was later withdrawn. The backlash damaged Biogen's reputation and, for a time, cast doubt on the entire amyloid-directed approach, raising questions about regulatory standards and payer willingness to back expensive, marginally effective therapies.

SHERIDAN, WYOMING - December 2, 2025 - As bispecifics, antibody-drug conjugates (ADCs), protein degraders and AI-designed mini-proteins move rapidly into clinical development, discovery teams are confronting a new bottleneck: not target ideas, but the practical engineering and scalable production of molecules that strain conventional biologics workflows.

From monoclonals to a radically more complex biologics toolbox

Monoclonal antibodies still anchor the biologics market, with more than 160 FDA approvals and a dominant share of global drug revenues. But the modality mix is shifting fast. More than 200 ADCs are now in clinical stages, bispecific approvals have climbed to 19 with sales above $12 billion in 2024, and regulators are increasingly supportive of novel protein formats.

SHERIDAN, WYOMING - December 2, 2025 - Microbial fermentation is moving back to the center of biologics manufacturing strategy, and contract development and manufacturing organizations (CDMOs) like AGC Biologics are under pressure to turn the platform's greatest strength-speed-into a reproducible, industrial-scale advantage.

Microbial fermentation's resurgence - and its speed problem

Microbial systems have long been valued for fast, efficient production of biologics, and they are now seeing renewed interest for a new generation of therapies. Yet the same speed that makes microbial fermentation attractive also makes it unforgiving. Typical production runs last around 48 hours, leaving very little time to diagnose and correct process deviations once a run is underway.

SHERIDAN, WYOMING - December 2, 2025 - As several large pharmas pull back from cell therapy, a core group of biopharma players is doubling down on CAR T and next-generation approaches, positioning themselves to capture long-term value in oncology and autoimmune disease even as near-term sentiment cools.

Big pharma exits reshape expectations, not potential

Over the past year, the cell therapy field has seen a string of high-profile retreats. Takeda halted new investments in the modality and is offloading its pipeline and platforms after more than eight years of heavy spending. Novo Nordisk followed by terminating all cell therapy work, including a type 1 diabetes program, with nearly 250 roles cut. Belgian biotech Galapagos also shut down its cell therapy business after failing to find a buyer.

SHERIDAN, WYOMING - December 2, 2025 - As consumer packaged goods companies head into 2026, Kellanova sees technology not as a back-office enabler but as a growth catalyst connecting insight to action, purpose to performance, and innovation to impact. From agentic AI to connected commerce and smart, sustainable supply chains, the company's leadership argues that digital transformation in CPG is now about reinvention, not just modernization.

Agentic AI moves from pilots to real business impact

Agentic AI is emerging as a force multiplier across the CPG value chain, capable of analyzing real-time data, making recommendations and executing actions without constant human intervention. In practice, that means automating repetitive tasks, streamlining cross-functional workflows and reacting to market shifts with new speed and precision.

SHERIDAN, WYOMING - November 28, 2025 - As DEKRA concludes its 100th anniversary year, the global testing, inspection and certification (TIC) organization is reporting resilient performance, mid-single digit revenue growth and a clear strategic course focused on Mobility, Digital Trust and Sustainability despite a volatile macroeconomic and geopolitical backdrop.

Resilient TIC Performance in a Challenging Environment

In 2025, DEKRA operated against a backdrop of elevated volatility, geopolitical uncertainties and weak economic conditions in several European markets. Even so, the group expects mid-single digit revenue growth for the full year and overall stable results at the level of the previous year. In the first ten months alone, revenue growth in the core TIC business stood at around 4 percent, underscoring the robustness of its service portfolio.

SHERIDAN, WYOMING - November 25, 2025 - In radiology, the most transformative AI of the coming decade may not be the algorithms that make headlines, but the ones that quietly shave minutes off every case, reduce clicks, and keep worklists flowing smoothly for overburdened imaging teams. That is the vision outlined by Shez Partovi, MD, Chief Innovation Officer and Chief Business Leader Enterprise Informatics at Philips, who argues that the future of AI in radiology is the AI you barely notice - deeply embedded into workflows rather than bolted on as yet another standalone tool.

From "Will it help?" to "How fast can you implement it?"